Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future

Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future

Lung cancer is worldwide the most common malignancy. Standard of care treatments for early-stage non-small-cell lung cancer (NSCLC) include surgery and adjuvant chemotherapy. However, these patients continue to have poor prognosis due to systemic or local relapse. Immunotherapy has been considered a...

Full description

Bibliographic Details
Main Authors: Chun Ho Szeto, Walid Shalata, Alexander Yakobson, Abed Agbarya
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Journal of Clinical Medicine
Subjects:
adjuvant
immune checkpoint inhibitors
immunotherapy
neoadjuvant
non-small-cell lung cancer (NSCLC)
Online Access:https://www.mdpi.com/2077-0383/10/23/5614

Similar Items

Similar Items